Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus R-HAD versus R-HAD in relapsed or refractory mantle cell lymphoma
2005-005144-62Phase 3Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, rituximab, cytarabine and dexamethasone in mantle cell lymphoma (MCL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Time to treatment failure. Started Oct 2010; status: completed.
02
Drugs
bortezomibrituximabcytarabinedexamethasone
03
Conditions
mantle cell lymphoma (MCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2005-005144-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005144-62.